

Supplementary Data for:

D-2-Hydroxyglutarate is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-induced *MIR148A* Promoter Methylation

Tie Li, Christopher D. Cox, Byram H. Ozer, Nhung T. Nguyen, HuyTram N. Nguyen, Thomas J. Lai, Sichen Li, Fei Liu, Harley I. Kornblum, Linda M. Liao, Phioanh L. Nghiemphu, Timothy F. Cloughesy, and Albert Lai

Supplementary Figure S1: Treatment with octyl-D-2-HG-induces *MIR148A* methylation

Supplementary Figure S2: Octyl-D-2-HG-induced *MIR148A* methylation status remains constant at late passages

Supplementary Figure S3: Octyl-D-2-HG induces CpG island methylation of the *RBPI* promoter in 293T cells

Supplementary Figure S4: Octyl-D-2-HG induces CpG island methylation of the *MIR148A* promoter in normal human astrocytes (NHA)

Supplementary Figure S5: *MIR148A* promoter CpG methylation in IDH1^{MUT}-transfected 293T cells

Supplementary Figure S6: C227 prevents IDH1 mutant-induced *MIR148A* promoter methylation

Supplementary Figure S7: C227 prevents IDH1 mutant-induced *RBPI* promoter methylation

Supplementary Figure S8: Schematic graph of *MIR148A* genomic location, CpG island, and promoter-reporter construct

Supplementary Figure S9: *MIR148a* expression is unchanged by octyl-D-2-HG treatment in early passages in 293T and NHA cells

Supplementary Figure S10: Octyl-D-2-HG withdrawal restores *MIR148A* promoter to an unmethylated state

Supplementary Figure S1: Treatment with octyl-D-2-HG-induces *MIR148A* methylation. Bis-Seq chromatogram images show octyl-D-2-HG-induced *MIR148A* methylation at passage 32. Top panel: untreated 293T cells. Middle panel: octyl-D-2-HG treated 293T cells. Bottom panel: methylation positive control of Sss I (methyltransferase)-treated DNA. Black arrows indicate methylated CpG sites (n=1).

Supplementary Figure S2: Octyl-D-2-HG-induced *MIR148A* methylation status remains constant at late passages. Bis-Seq chromatogram images show octyl-D-2-HG-induced *MIR148a* methylation at passages 35, 40 and 45. Octyl-D-2-HG treatment beyond passage 35 does not result in a further increase in *MIR148A* methylation levels. Black arrowheads indicate methylated CpG sites (n=1).

Supplementary Figure S3: Octyl-D-2-HG induces CpG island methylation of the *RBPI* promoter in 293T cells. Chromatogram images of *RBPI* promoter methylation status determined by Bis-Seq in control and octyl-D-2-HG treated 293T cells (passage 40 of treatment). Black arrowheads indicate methylated CpG sites (n=1).

Supplementary Figure S4: Octyl-D-2-HG induces CpG island methylation of the *MIR148A* promoter in normal human astrocytes (NHA). **A:** Octyl-D-2-HG elevates D-2-HG levels in NHA cells (passage 2-4). Figure shows an increase in intracellular levels after 2 days of treatment (0.5 mM) (n=2, bars show SEM). **B:** Chromatogram images of *MIR148A* promoter methylation status determined by Bis-Seq in control (passage 4) and octyl-D-2-HG treated NHA cells (passage 0, 2 and 4). Black arrowheads indicate methylated CpG sites at passage 2 (with very weak C peaks at CpG sites 5, 7 and 8) and passage 4 (with stronger C peaks from CpG site 5 through 12). Site 6 (open arrowhead) remains unmethylated. **C:** Chromatogram images of *MIR148A* methylation induced by octyl- α -KG and octyl-L-2-HG in NHA cells. Statistical analysis for bar graph performed using two-tailed student t-test. *** indicates p<0.001, ** indicates p<0.01 and * indicates p<0.05 compared with control. Black arrowheads in chromatogram images indicate methylated CpG sites. Site 6 (open arrowhead) remains unmethylated (n=1).

Supplementary Figure S5: *MIR148A* promoter CpG methylation in IDH1^{MUT}-transfected 293T cells (passage 27). Chromatogram in top panel shows the Bis-Seq result. Bottom panel shows the T-A cloning result in a lollipop diagram. Black arrowheads indicate methylated CpG sites (n=1).

Supplementary Figure S6: C227 prevents *IDH1* mutant-induced *MIR148A* promoter methylation. Chromatogram images of *MIR148a* Bis-Seq in empty vector (top), and IDH1^{MUT}-293T cells without (middle) and with (bottom) C227 treatment at passage 40. C227 prevents the development of *MIR148A* promoter methylation in IDH1^{MUT}-293T cells. Black arrowheads indicate methylated CpG sites (n=1).


Supplementary Figure S7: C227 prevents *IDH1* mutant-induced *RBPI* promoter methylation. Chromatogram images of *RBPI* Bis-Seq in IDH1^{MUT}-293T cells without (top) and with (bottom) C227 treatment (41 passages). C227 prevents the development of *RBPI* promoter methylation in IDH1^{MUT}-293T cells. Black arrowheads indicate methylated CpG sites (n=1).

Supplementary Figure S8: Schematic graph of *MIR148A* genomic location, CpG island, and promoter-reporter construct. Black arrows indicate Bis-Seq regions, and white arrows indicate the region cloned into the pGL vector. Location within the UCSC Genome Browser is shown. Expanded from **Figure 3B**.


Supplementary Figure S9: *MIR148a* expression is unchanged by octyl-D-2-HG treatment in early passages in 293T and NHA cells. **A:** *MIR148a* expression in early passages (p10-p15) of D-2-HG-treated 293T cells. Analysis by RT-qPCR showed no significant difference in 293T cells treated with D-2-HG versus vehicle (average of 10 and 15 passages of treatment). **B:** *MIR148a* expression in early passages (p2) of NHA cells treated with octyl- α -KG, -D-2-HG and -L-2-HG. Analysis by RT-qPCR showed no significant difference in NHA cells treated with octyl- α -KG, -D-2-HG and -L-2-HG versus vehicle for 2 passages. Bars show SEM (n=2). Statistical analysis in graphs performed using two-tailed student t-test. ns indicates no significance.

Supplementary Figure S10: Octyl-D-2-HG withdrawal restores *MIR148A* promoter to an unmethylated state. Bis-Seq chromatogram images show *MIR148A* with continued octyl-D-2-HG treatment versus withdrawal. Top panel shows octyl-D-2-HG-treated 293T cells (passage 48). Middle panel shows demethylation following octyl-D-2-HG withdrawal (passage 48; 8 passages post-withdrawal). Bottom panel shows methylation positive control of Sss I (methyltransferase)-treated DNA. Black arrowheads indicate methylated CpG sites (n=1).


Supplementary Figure S1



Supplementary Figure S2




Supplementary Figure S3




Supplementary Figure S4


A





B



C




Supplementary Figure S5




○ CpG: U ● CpG: M

Supplementary Figure S6



Supplementary Figure S7





Supplementary Figure S8

UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly

move <<< << < > >> >>> zoom in 1.5x 3x 10x base zoom out 1.5x 3x 10x 100x


chr7:25,989,289-25,992,042 2,754 bp. enter position, gene symbol, HGVS or search terms

go




Supplementary Figure S9

A



B



Supplementary Figure S10

